Frank R G, Kashani J H, Parker J C, Beck N C, Brownlee-Duffeck M, Elliott T R, Haut A E, Atwood C, Smith E, Kay D R
Multipurpose Arthritis Center, School of Medicine, University of Missouri-Columbia.
J Rheumatol. 1988 Nov;15(11):1632-8.
Forty-seven patients with definite rheumatoid arthritis (RA) were treated in a 32 week, double blind, crossover trial of amitriptyline, desipramine, trazodone, and placebo. All drug regimens produced significant changes on pain measures relative to baseline, but only amitriptyline exceeded placebo. Amitriptyline was associated with a significant reduction in the number of painful/tender joints. Our study supports the efficacy of a moderate dose of amitriptyline as an adjunct drug for the treatment of pain in both depressed and nondepressed patients with RA.
47例确诊为类风湿性关节炎(RA)的患者参与了一项为期32周的双盲交叉试验,该试验涉及阿米替林、地昔帕明、曲唑酮和安慰剂。相对于基线水平,所有药物治疗方案在疼痛指标上均产生了显著变化,但只有阿米替林的效果超过了安慰剂。阿米替林与疼痛/压痛关节数量的显著减少相关。我们的研究支持中等剂量的阿米替林作为辅助药物治疗RA抑郁和非抑郁患者疼痛的疗效。